Literature DB >> 23276809

Currently available medications in resource-rich settings may not be sufficient for lifelong treatment of HIV.

James Jansson1, David P Wilson, Andrew Carr, Kathy Petoumenos, Mark A Boyd.   

Abstract

OBJECTIVE: Combination antiretroviral therapy (cART) has greatly improved the life expectancy of people living with HIV (PLHIV). Our study aims to project the life expectancy of PLHIV in a resource-rich setting in the context of the currently available antiretroviral treatments.
METHODS: Patient antiretroviral treatment data were sourced from an observational cohort of 3434 predominantly male (94.2%) PLHIV in Australia over the period 1997-2010. These data were analyzed in a computer simulation model to calculate the distribution of time until exhaustion of all treatment options and expected effect on mortality. Standardized mortality ratios were used to simulate expected survival before and after treatment exhaustion.
RESULTS: We estimated that the median time until exhaustion of currently available treatment options is 45.5 years [interquartile range (IQR) 34.0-61.0 years]. However, 10% of PLHIV are expected to exhaust all currently available cART options after just 25.6 years. PLHIV who start currently available cART regimens at age 20 years are expected to live to a median age of 67.4 (IQR 53.2-77.7) years. This is a substantial improvement on no cART [27.7 (IQR 23.8-32.0) years] but is still substantially less than the median general population mortality age [82.2 (IQR 74.0-87.8) years]. The life expectancy gap between PLHIV and the general population is greatest for those infected at younger ages.
CONCLUSION: As treatment options are exhausted, a substantial difference in life expectancy between PLHIV and the general population could be expected even in resource-rich settings, particularly for people who acquire HIV at a younger age or who are currently highly treatment experienced.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23276809      PMCID: PMC3740079          DOI: 10.1097/QAD.0b013e32835e163d

Source DB:  PubMed          Journal:  AIDS        ISSN: 0269-9370            Impact factor:   4.177


  19 in total

1.  Survival of persons with and without HIV infection in Denmark, 1995-2005.

Authors:  Nicolai Lohse; Ann-Brit Eg Hansen; Gitte Pedersen; Gitte Kronborg; Jan Gerstoft; Henrik Toft Sørensen; Michael Vaeth; Niels Obel
Journal:  Ann Intern Med       Date:  2007-01-16       Impact factor: 25.391

2.  AIDS-related and non-AIDS-related mortality in the Asia-Pacific region in the era of combination antiretroviral treatment.

Authors:  Kathleen Falster; Jun Yong Choi; Basil Donovan; Chris Duncombe; Brian Mulhall; David Sowden; Jialun Zhou; Matthew G Law
Journal:  AIDS       Date:  2009-11-13       Impact factor: 4.177

Review 3.  An updated systematic overview of triple combination therapy in antiretroviral-naive HIV-infected adults.

Authors:  John A Bartlett; Michael J Fath; Ralph Demasi; Ashwaq Hermes; Joseph Quinn; Elsa Mondou; Franck Rousseau
Journal:  AIDS       Date:  2006-10-24       Impact factor: 4.177

Review 4.  Improvements in antiretroviral therapy outcomes over calendar time.

Authors:  Mark A Boyd
Journal:  Curr Opin HIV AIDS       Date:  2009-05       Impact factor: 4.283

5.  Changes in mortality following HIV and AIDS and estimation of the number of people living with diagnosed HIV/AIDS in Australia, 1981-2003.

Authors:  Fatemeh Nakhaee; Deborah Black; Handan Wand; Ann McDonald; Matthew Law
Journal:  Sex Health       Date:  2009-06       Impact factor: 2.706

6.  Inferior clinical outcome of the CD4+ cell count-guided antiretroviral treatment interruption strategy in the SMART study: role of CD4+ Cell counts and HIV RNA levels during follow-up.

Authors:  Jens D Lundgren; Abdel Babiker; Wafaa El-Sadr; Sean Emery; Birgit Grund; James D Neaton; Jacquie Neuhaus; Andrew N Phillips
Journal:  J Infect Dis       Date:  2008-04-15       Impact factor: 5.226

7.  Changes in the risk of death after HIV seroconversion compared with mortality in the general population.

Authors:  Krishnan Bhaskaran; Osamah Hamouda; Mette Sannes; Faroudy Boufassa; Anne M Johnson; Paul C Lambert; Kholoud Porter
Journal:  JAMA       Date:  2008-07-02       Impact factor: 56.272

8.  Rates of combination antiretroviral treatment change in Australia, 1997-2000.

Authors: 
Journal:  HIV Med       Date:  2002-01       Impact factor: 3.180

9.  Life expectancy of individuals on combination antiretroviral therapy in high-income countries: a collaborative analysis of 14 cohort studies.

Authors: 
Journal:  Lancet       Date:  2008-07-26       Impact factor: 79.321

10.  Long-term survival in HIV positive patients with up to 15 Years of antiretroviral therapy.

Authors:  Hamish McManus; Catherine C O'Connor; Mark Boyd; Jennifer Broom; Darren Russell; Kerrie Watson; Norman Roth; Phillip J Read; Kathy Petoumenos; Matthew G Law
Journal:  PLoS One       Date:  2012-11-07       Impact factor: 3.240

View more
  6 in total

1.  Funding antiretroviral treatment for HIV-positive temporary residents in Australia prevents transmission and is inexpensive.

Authors:  Richard T Gray; Jo Watson; Aaron J Cogle; Don E Smith; Jennifer F Hoy; Lisa A Bastian; Robert Finlayson; Fraser M Drummond; Bill Whittaker; Matthew G Law; Kathy Petoumenos
Journal:  Sex Health       Date:  2018-02       Impact factor: 2.706

2.  'Not Until I'm Absolutely Half-Dead and Have To:' Accounting for Non-Use of Antiretroviral Therapy in Semi-Structured Interviews with People Living with HIV in Australia.

Authors:  Christy E Newman; Limin Mao; Asha Persson; Martin Holt; Sean Slavin; Michael R Kidd; Jeffrey J Post; Edwina Wright; John de Wit
Journal:  AIDS Patient Care STDS       Date:  2015-03-25       Impact factor: 5.078

3.  Treatment durability and virological response in treatment-experienced HIV-positive patients on an integrase inhibitor-based regimen: an Australian cohort study.

Authors:  Nicole L De La Mata; David A Cooper; Darren Russell; Don Smith; Ian Woolley; Maree O Sullivan; Stephen Wright; Matthew Law
Journal:  Sex Health       Date:  2016-04-21       Impact factor: 2.706

4.  Projection of age of individuals living with HIV and time since ART initiation in 2030: estimates for France.

Authors:  Lise Marty; Yakhara Diawara; Antoine Rachas; Sophie Grabar; Dominique Costagliola; Virginie Supervie
Journal:  J Int AIDS Soc       Date:  2022-09       Impact factor: 6.707

Review 5.  Efficacy of initial antiretroviral therapy for HIV-1 infection in adults: a systematic review and meta-analysis of 114 studies with up to 144 weeks' follow-up.

Authors:  Frederick J Lee; Janaki Amin; Andrew Carr
Journal:  PLoS One       Date:  2014-05-15       Impact factor: 3.240

6.  A Prognostic Model to Assess Long-Term Survival of Patients on Antiretroviral Therapy: A 15-Year Retrospective Cohort Study in Southwestern China.

Authors:  He Jiang; Qiuying Zhu; Yi Feng; Jinghua Huang; Zongxiang Yuan; Xinjuan Zhou; Guanghua Lan; Hao Liang; Yiming Shao
Journal:  Open Forum Infect Dis       Date:  2021-06-12       Impact factor: 3.835

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.